|
It is one of the newer APs, relatively speaking. It might not have been approved for maintenance treatment yet, which does not mean it is not effective this way. It just has not been clinically tested enough to gain an extra indication FDA approval.
__________________
Bipolar I w/psychotic features
Last inpatient stay in 2018
Lybalvi 10 mg
Naltrexone 75 mg
Gabapentin 1500 mg+Vitamin B-complex (against extrapyramidal side effects)
Long-term side effects from medications, some of them discontinued:
- Hypothyroidism
- Obesity BMI ~ 38
|